Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
Date:9/29/2008

SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Monday, October 6 at 1:30pm Eastern Time (10:30am Pacific Time) during the JMP Securities Third Annual Healthcare Focus Conference at the Le Parker Meridien Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in- licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter- related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor Relations

Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.

858-436-1400 858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
5. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
7. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ... active lead drug candidate, PBI-4050, has been issued a ... and Healthcare Products Regulatory Agency ("MHRA") for the treatment ... designation is an early indication that a medicinal product ... Medicines Scheme ("EAMS"), intended for the treatment, diagnosis or ...
(Date:1/24/2017)... ... January 23, 2017 , ... Edward ... first-ever recipient of the National Academy of Sciences Prize in Food and Agriculture ... nutrition. , The annual National Academy of Sciences (NAS) Prize in Food and ...
(Date:1/24/2017)... , Jan. 23, 2017  Recognizing the ... on scientific discovery and solutions, the University of ... Frost Institutes for Science and Engineering to achieve ... mathematics (STEM) to help solve some of the ... Miami President Julio Frenk unveiled the ...
(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
Breaking Biology Technology:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
(Date:12/15/2016)... --  WaferGen Bio-systems, Inc. (NASDAQ: WGBS ... that on December 13, 2016, it received a letter ... Market LLC which acknowledged that, as of December 12, ... had been at $1.00 or greater for ten consecutive ... Rule 5550(a)(2) of the Nasdaq Stock Market. ...
Breaking Biology News(10 mins):